agreement, 3) $4.5 million loss on the permanent impairment of equity investments, 4) $2.0 million gain on the sale of divested pharmaceutical products in Brazil, 5) $4.2 million unrealized gain on derivative instruments, and 6) $4.4 million associated with the 2002 spin-off of the Company’s ophthalmic surgical and contact lens care businesses. The adjusted amounts in 2000 exclude the after-tax effects of the following: 1) a $0.2 million restructuring charge, 2) $1.3 million gain on the sale of investments, and 3) $2.0 million in expenses from partnering agreements. The adjusted amounts in 1999 exclude the after-tax effects of the following: 1) $3.6 million in restructuring charge reversals, 2) $0.8 million in asset gains, reducing write-offs recorded in 1998, 3) $14.0 million gain on sales of investments, 4) $6.9 million contribution to The Allergan Foundation, 5) $3.8 million of income, net of expenses of $5.7 million, from partnering agreements, and 6) $1.1 million in certain one-time costs. (b)Diluted earnings per share adjusted by $0.04 for the first six months of 2002 and by $0.07 for the full year 2001 to reflect dissynergies related to the spin-off of Advanced Medical Optics. The foregoing presentation contains certain non-GAAP financial measures, including con- stant currency growth rates, and non-GAAP and  pro forma adjustments. For a reconciliation of these non-GAAP financial measures to comparable GAAP financial measures, please refer to pages 6 and 7 of this Annual Report. financial overview In millions, except per share data 2003 2002 2001 2000 1999 STATEMENT OF OPERATIONS HIGHLIGHTS (As reported under U.S. GAAP) Product net sales $1,755.4 $1,385.0 $1,142.1 $992.1 $828.6 Gross profit 1,435.1 1,163.3 944.0 794.4 658.2 Research and development 763.5 233.1 227.5 165.7 140.6 Earnings (loss) from continuing operations (52.5) 64.0 171.2 165.9 143.7 Earnings from discontinued operations – 11.2 54.9 49.2 44.5 Net earnings (loss) (52.5) 75.2 224.9 215.1 188.2 Basic earnings (loss) per share: Continuing operations (0.40) 0.49 1.30 1.27 1.09 Discontinued operations – 0.09 0.42 0.38 0.33 Diluted earnings (loss) per share: Continuing operations (0.40) 0.49 1.29 1.24 1.06 Discontinued operations – 0.08 0.40 0.37 0.33 Dividends per share 0.36 0.36 0.36 0.32 0.28 ADJUSTED AMOUNTS ( a ) Adjusted earnings from continuing operations 305.2 252.3 207.7 166.6 133.9 Adjusted basic earnings per share from continuing operations 2.34 1.95 1.58 1.27 1.01 Adjusted diluted earnings per share  from continuing operations 2.31 1.92 1.55 1.25 0.99 Pro forma diluted earnings per share from continuing  operations adjusted for dissynergies related to spin-off of Advanced Medical Optics, Inc. ( b ) 2.31 1.88 1.48 – – NET SALES BY PRODUCT LINE  Specialty Pharmaceuticals: Eye Care Pharmaceuticals $ 999.5 $ 827.3 $ 753.7 $683.9 $576.2 BOTOX/Neuromodulators 563.9 439.7 309.5 239.5 175.8 Skin Care 109.3 90.2 78.9 68.7 76.6 Total Pharmaceutical Sales 1,672.7 1,357.2 1,142.1 992.1 828.6 Other 82.7 27.8 – – – Total Net Sales 1,755.4 $1,385.0 $1,142.1 $992.1 $828.6 PRODUCTS SOLD BY LOCATION Domestic 70.4% 70.6% 67.0% 63.4% 60.7% International 29.6% 29.4% 33.0% 36.6% 39.3% Year Ended December 31,